Stocks of the Hour: Mesoblast, Andromeda Metals, Imugene
Stocks of the Hour: Mesoblast, Andromeda Metals, Imugene
Mesoblast (ASX:MSB; Nasdaq:MESO) announced that the United States Food and Drug Administration (FDA) has granted its allogeneic cell therapy Revascor, a Rare Pediatric Disease (RPD) Designation. This follows the submission of results from the randomised controlled trial in children with hypoplastic left heart syndrome (HLHS), a potentially life threatening congenital heart condition. Shares are trading 18.87 per cent higher at 31.5 cents
Mesoblast(澳大利亞證券交易所股票代碼:MSB;納斯達克股票代碼:MESO)宣佈,美國食品藥品監督管理局(FDA)已授予其異體細胞療法Revascor罕見兒科疾病(RPD)稱號。在此之前,針對左心發育不全綜合症(HLHS)(一種可能危及生命的先天性心臟病)患兒的隨機對照試驗結果提交了結果。股價上漲18.87%,至31.5美分
Andromeda Metals (ASX:ADN) has entered into a sales and distribution agreement (Agreement) for Andromeda's high-quality kaolin products into the Mediterranean region, with IberoClays SLU. Under the Agreement, the parties agree to terms for the sale and purchase of the following: Great White CRM for sale into the ceramics and tile sectors, and Great White HRM for sale into the concrete industry. Shares are trading flat at 2.6 cents.
仙女座金屬(澳大利亞證券交易所股票代碼:ADN)已與IberoClays SLU簽訂了向地中海地區銷售和分銷仙女座高嶺土產品的銷售和分銷協議(協議)。根據該協議,雙方同意以下產品的銷售和購買條款:向陶瓷和瓷磚行業出售Great White CRM,向混凝土行業出售Great White HRM。股價持平至2.6美分。
Imugene (ASX:IMU) has announced that its Phase 1 MAST (metastatic advanced solid tumours) trial, evaluating the safety of novel cancer-killing virus, has continued to progress with the first patients dosed in each arm of the higher dose cohort as part of the Phase 1 study. In the trial, 24 patients to date dosed in monotherapy arms with no safety issues observed, and 38 patients enrolled in trial to date across monotherapy and combination arms. Shares are trading 7.5 per cent higher at 10.75 cents.
Imugene(澳大利亞證券交易所股票代碼:IMU)宣佈,其評估新型殺癌病毒安全性的1期MAST(晚期轉移性實體瘤)試驗繼續取得進展,作爲1期研究的一部分,高劑量隊列的每個組均爲首批患者給藥。在該試驗中,迄今爲止,有24名患者在單一療法組中給藥,未觀察到任何安全問題,迄今爲止,有38名患者參加了單一療法和聯合療法組的試驗。股價上漲7.5%,至10.75美分。
譯文內容由第三人軟體翻譯。